Pozen's stock price plunged 46 percent in Thursday trading, after the drugmaker and its partner GlaxoSmithKline got sent back to the drawing board by the FDA.
The agency demanded more data before it would approve Trexima, its triptan/NSAIDl painkiller for migraines, said Pozen and GlaxoSmithKline.
The announcement came as a shock to investors. In Wednesday trading ahead of the announcement, Pozen's stock jumped 8 percent as investors bet on FDA approval.
No comments:
Post a Comment